Develops therapeutic products for cancer and infectious diseases. Utilizes a proprietary Tarmogen platform to stimulate specific T-cell immune responses. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 6% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $6.5M a year. A small number, but proof the product has real buyers.
There is $9.9M in the vault; even if every debt were paid off, $9.9M would remain.
Over the last 12 months, company executives reported 1 buy and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $2.8M against $6.5M in annual sales.
The stock sits at $0.0001. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.